Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors.

MLA

Jaiswal, Bijay S., et al. “Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors.” PLoS ONE, vol. 4, no. 5, May 2009, pp. 1–12. EBSCOhost, https://doi.org/10.1371/journal.pone.0005717.

APA

Jaiswal, B. S., Janakiraman, V., Kljavin, N. M., Eastham-Anderson, J., Cupp, J. E., Yuxin Liang, Davis, D. P., Klaus P. Hoeflich, & Seshagiri, S. (2009). Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors. PLoS ONE, 4(5), 1–12. https://doi.org/10.1371/journal.pone.0005717

Chicago

Jaiswal, Bijay S., Vasantharajan Janakiraman, Noelyn M. Kljavin, Jeffrey Eastham-Anderson, James E. Cupp, Yuxin Liang, David P. Davis, Klaus P. Hoeflich, and Somasekar Seshagiri. 2009. “Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors.” PLoS ONE 4 (5): 1–12. doi:10.1371/journal.pone.0005717.